Novo Nordisk

News

Shares in Eli Lilly have weakened after pharmacy benefit manager CVS Health said it would no longer cover its weight-loss therapy Zepbound.

News

Novo Nordisk has enlisted the aid of major telehealth companies as it tries to dominate the self-pay market for obesity drugs in the US.

News

Novo Nordisk has seen its first lawsuit over the proposed link between Ozempic and the rare eye disorder NAION.

News

A proposal by the Biden administration to cover weight-loss medicines for obesity under Medicare has been axed by the White House.

News

Novo Nordisk's Ozempic has been shown to improve walking distance in people with diabetes and peripheral artery disease in the STRIDE trial.

Market Access

Recent advancements in weight-loss interventions are transforming the healthcare landscape and presenting new M&A opportunities